Evidence map›Paper›PMID 34456540›Full record

ArticleRussian journal of bioorganic chemistry2021

Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients.

Zahraa Talib Khudhair, Mehdi Salih Shihab, Baram Hamah-Ameen

Open access · bronzeAbstract read
In one paragraph

Article in Russian journal of bioorganic chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Zahraa Talib KhudhairPharmacy Department, Al- Esraa University College, 10001 Baghdad, Iraq.
Mehdi Salih ShihabChemistry Department, College of Science, Al-Nahrain University, 10001 Baghdad, Iraq.
Baram Hamah-AmeenChemistry Department, College of Science, University of Sulaimani, 46001 Sulaimaneyah, Iraq.
Al Mansour University College · IQNahrain University · IQUniversity of Sulaimani · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The drug development process for Coronavirus disease (COVID-19) is the research process to create a preventive vaccine or therapeutic prescription drug to relieve the severity of 2019-2020 (COVID-19). In different stages of preclinical or clinical research, several hundred special scientific research centers, research organizations, and health agencies have developed and tried enormous numbers of vaccine candidates and new drugs for COVID-19 disease. In order to identify new therapies against COVID-19, several clinical trials have been in progress worldwide.

Indexed as

Coronavirus diseasedrug development processFavipiravirLosartantrial of treatments

Identifiers

PMID34456540
PMCPMC8380022
OpenAlexW3194509414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.